{"title":"Autoimmune pulmonary alveolar proteinosis developed during treatment for systemic sclerosis: a case report.","authors":"Tomoki Kozono, Kentaro Tanaka, Tomoko Yagi, Kazuto Kamikawaji, Masaki Watanabe, Azusa Iwanaga, Minako Hamada, Yoshifusa Koreeda, Hiromasa Inoue, Ikkou Higashimoto","doi":"10.1186/s12890-025-03489-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Reports of autoimmune diseases coexisting with autoimmune pulmonary alveolar proteinosis (autoimmune PAP; APAP) are extremely rare. APAP coexisting with autoimmune diseases may often be misdiagnosed as connective tissue disease-associated interstitial lung disease (ILD). Here, we describe a rare case of a patient with systemic sclerosis who was diagnosed with APAP after the exacerbation of lung opacities during treatment with immunosuppressive agents.</p><p><strong>Case presentation: </strong>A 72-year-old woman was diagnosed with systemic sclerosis (SSc) at the age of 68, and initiated treatment with prednisolone (PSL). At the age of 70, she was diagnosed with ILD associated with SSc. Despite intravenous cyclophosphamide (IVCY), no improvement was observed. A significant elevation of Krebs von den Lungen-6 (KL-6) and a crazy-paving pattern on chest computed tomography (CT) are observed. Bronchoscopy showed milky white bronchoalveolar lavage fluid (BALF) and histology of periodic acid-Schiff (PAS) stain-positive eosinophilic granular material. Serum anti granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies were measured, and the result was positive, leading to the diagnosis of APAP.</p><p><strong>Conclusion: </strong>In patients with interstitial lung shadows who do not improve with immunosuppressive treatment, PAP is one of the differential diagnoses that should be considered. All physicians should be aware that the appropriate diagnosis of PAP and the measurement of serum anti-GM-CSF antibodies will critically affect patient outcomes.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"32"},"PeriodicalIF":2.6000,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11753109/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Pulmonary Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12890-025-03489-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Reports of autoimmune diseases coexisting with autoimmune pulmonary alveolar proteinosis (autoimmune PAP; APAP) are extremely rare. APAP coexisting with autoimmune diseases may often be misdiagnosed as connective tissue disease-associated interstitial lung disease (ILD). Here, we describe a rare case of a patient with systemic sclerosis who was diagnosed with APAP after the exacerbation of lung opacities during treatment with immunosuppressive agents.
Case presentation: A 72-year-old woman was diagnosed with systemic sclerosis (SSc) at the age of 68, and initiated treatment with prednisolone (PSL). At the age of 70, she was diagnosed with ILD associated with SSc. Despite intravenous cyclophosphamide (IVCY), no improvement was observed. A significant elevation of Krebs von den Lungen-6 (KL-6) and a crazy-paving pattern on chest computed tomography (CT) are observed. Bronchoscopy showed milky white bronchoalveolar lavage fluid (BALF) and histology of periodic acid-Schiff (PAS) stain-positive eosinophilic granular material. Serum anti granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies were measured, and the result was positive, leading to the diagnosis of APAP.
Conclusion: In patients with interstitial lung shadows who do not improve with immunosuppressive treatment, PAP is one of the differential diagnoses that should be considered. All physicians should be aware that the appropriate diagnosis of PAP and the measurement of serum anti-GM-CSF antibodies will critically affect patient outcomes.
背景:自身免疫性疾病与自身免疫性肺泡蛋白沉积症(autoimmune PAP;APAP)极为罕见。APAP合并自身免疫性疾病常被误诊为结缔组织病相关间质性肺病(ILD)。在这里,我们描述了一例罕见的系统性硬化症患者,在使用免疫抑制剂治疗期间肺混浊加剧后被诊断为APAP。病例介绍:一名72岁的女性在68岁时被诊断为系统性硬化症(SSc),并开始使用强的松龙(PSL)治疗。70岁时,她被诊断为伴有SSc的ILD。尽管静脉注射环磷酰胺(IVCY),没有观察到改善。在胸部CT上观察到Krebs von den Lungen-6 (KL-6)明显升高和疯狂铺路模式。支气管镜检查示乳白色支气管肺泡灌洗液(BALF),组织学为周期性酸希夫(PAS)染色阳性嗜酸性颗粒物质。检测血清抗粒细胞-巨噬细胞集落刺激因子(GM-CSF)抗体,结果为阳性,诊断为APAP。结论:免疫抑制治疗后间质性肺影无改善的患者,PAP是应考虑的鉴别诊断之一。所有医生都应该意识到PAP的适当诊断和血清抗gm - csf抗体的测量将严重影响患者的预后。
期刊介绍:
BMC Pulmonary Medicine is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of pulmonary and associated disorders, as well as related molecular genetics, pathophysiology, and epidemiology.